|
|
Post by MnkdWASmyRtrmntPlan on Jun 2, 2021 19:59:22 GMT -5
Here's a little good news amidst all the bad stuff goin on. A consensus of 6 analysts says "breakeven" in 2 years (2023). 6 Analysts articleAnd here is the nice source report: Simply Wall Street source report
Their earnings projection graphs look more like January 2024 to me, but hey, close enough. MC bought 8,000 shares this year and 45,431 last year. That's kinda nice. |
|
|
|
Post by Clement on Jun 3, 2021 7:23:11 GMT -5
Here's a little good news amidst all the bad stuff goin on. A consensus of 6 analysts says "breakeven" in 2 years (2023). 6 Analysts article"According to the 6 industry analysts covering MannKind, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2022, before generating positive profits of US$1.9m in 2023. The company is therefore projected to breakeven around 2 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2023? Working backwards from analyst estimates, it turns out that they expect the company to grow 70% year-on-year, on average, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict." |
|
|
|
Post by mango on Jun 3, 2021 12:18:39 GMT -5
UT expects around 70% conversion from Tyvaso nebulizer to Tyvaso DPI within the first 4 months post-FDA approval.
So, we will be generating handsome royalties extremely soon after FDA approval—which will be during Q4 this year.
|
|
|
|
Post by mytakeonit on Jun 3, 2021 13:53:36 GMT -5
Breakeven is great ... but, we don't need that for MNKD share price to climb. News like this will give us positive direction.
So? Buy all the cheap shares that you can !!!
But, that's mytakeonit
|
|
|
|
Post by radgray68 on Jun 3, 2021 20:53:28 GMT -5
I remember a note put out by Goldman Sachs around the time Sanofi dropped us. It may even have been their final note before they dropped coverage on our stock. Anyway, the Goldman analyst said, and I'm paraphrasing, If Mannkind goes the route of selling Afrezza with their own salesforce, they will not turn profitable until 2023.
I was shocked. I remember being so pissed at that guy and thought for sure he was just another short. What does he know? Etc. etc. etc. Boy, fast-forward about 5 years and I'm thinking that Goldman guy knew exactly what he was talking about.
On the bright side, mytake is right. I don't believe we have to wait until profitability to lift our stock price from here. Too many other good things coming before then. Tyvaso, other partnerships, an unexpected inflection in Afrezza sales, and my heartfelt favorite: Peds trial results. GLTA
|
|
|
|
Post by veritasfiliatemporis on Jun 4, 2021 3:15:51 GMT -5
Some doubts on Peds trial....
|
|
|
|
Post by dh4mizzou on Jun 4, 2021 6:20:03 GMT -5
Some doubts on Peds trial.... FUD much? |
|
|
|
Post by veritasfiliatemporis on Jun 4, 2021 7:39:29 GMT -5
Some doubts on Peds trial.... FUD much? Realistic.. |
|
|
|
Post by cretin11 on Jun 4, 2021 8:30:25 GMT -5
Obviously you are just a FUDster. Pessimism not allowed here. |
|
|
|
Post by veritasfiliatemporis on Jun 4, 2021 8:43:34 GMT -5
Better than a cretin, I presume...
|
|
|
|
Post by veritasfiliatemporis on Jun 4, 2021 8:45:55 GMT -5
Better than a cretin, I presume... David... |
|
|
|
Post by cretin11 on Jun 4, 2021 8:47:14 GMT -5
Neither pessimists, fudsters nor cretins are appreciated here... or are they all one and the same?
|
|
|
|
Post by Clement on Jun 4, 2021 8:48:34 GMT -5
It's gonna be that kind of day. Thanks, guys!
|
|
|
|
Post by dh4mizzou on Jun 4, 2021 9:24:32 GMT -5
Obviously you are just a FUDster. Pessimism not allowed here. In my opinion " Some doubts on Peds trial...." posting comments like this without providing some form of substantiation would fall into the FUD category. |
|
|
|
Post by akemp3000 on Jun 4, 2021 9:45:04 GMT -5
Agreed. To post a negative perspective without any substance to explain the thought or logic has to be considered FUD. It's like any argument when the losing side has nothing better to say other than to resort to name calling. The opportunity certainly exists to follow up and explain why there are "some doubts on the Peds trial. IMO, nothing published or posted to date should lead anyone to think this.
|
|
